Many ingredients in herbal tea can interact with prescription medications. Blood thinners, transplant medications, and antidepressants are just a few of the medications that should be avoided.

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Several of the largest US and European drugmakers struck agreements with President Donald Trump ...

President Donald Trump on Friday afternoon announced that nine major pharmaceutical companies have agreed to join his "most favored nation" pricing policy, bringing down the price of prescription ...

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer ...

Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free ...

WASHINGTON, Dec ‌18 (Reuters) - Americans enrolled in Medicare will ‌pay about 50% less out of pocket in 2026 for some drugs including Pfizer and Bristol Myers Squibb's blood thinner Eliquis and Merck ...

Andexanet alfa (Andexxa) will officially be taken off the U.S. market this month as an emergency reversal medication for contemporary blood thinners. "The Biologics License Application for Andexxa has ...

Dear Dr. Roach: In 1998, I was diagnosed with lupus anticoagulant and was put on Coumadin. I tolerated it well. A couple of years ago, I was changed to Eliquis, which I also tolerate well. I noticed ...

DEAR DR. ROACH: In 1998, I was diagnosed with lupus anticoagulant and was put on Coumadin. I tolerated it well. A couple of years ago, I was changed to Eliquis, which I also tolerate well. I noticed ...

Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation with a stent planted at least 1 year prior, oral anticoagulation ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog. The Trump administration announced in August ...